Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

NCT03088176 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

4

Enrollment

OTHER

Sponsor class

Conditions

Melanoma
BRAF Gene Mutation

Interventions

DRUG: Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil
DRUG: Talimogene Laherparep 100 Mil Pfu/Ml 1Ml
DRUG: Dabrafenib
DRUG: Trametinib

Sponsor

West Cancer Center

Collaborators

[object Object]
[object Object]